Pediatricians who prescribe continuous glucose monitors to high risk kids and those who fear eating disorders are split on whether healthy children should wear one.
The FDA cleared Dexcom's Stelo in June 2026 for over-the-counter purchase in children 2 and older, the first continuous glucose monitor cleared for over-the-counter sale to children that young. The decision covers the Stelo Glucose Biosensor System, a small wearable that pierces the skin and reads interstitial glucose every 15 minutes, day and night. The FDA cleared Stelo through its 510(k) medical-device pathway, submission K260935, which treats new devices as substantially equivalent to existing predicate devices. The FDA's stated rationale: real-time glucose data can help caregivers and pediatric patients build glycemic awareness and track the meal and exercise patterns that drive long-term outcomes.
Wendy Schofer, a pediatrician who specializes in eating disorder prevention, told STAT News the move is premature and warned that round-the-clock glucose readings in kids without diabetes risk hyperfocus, panic, and restrictive eating. That warning is one side of a split STAT's reporting documents: clinicians who already prescribe CGMs to high-risk pediatric patients see value in earlier access and would rather a parent reach for a sensor than wait months for a pediatric endocrinology visit.
The FDA's clearance shifts the device out of the pediatric endocrinology clinic and into direct consumer reach. Until the June clearance, a parent who wanted a CGM on a 2-year-old had to find a pediatric specialist willing to prescribe one. Now any caregiver can purchase a sensor for a young child without going through a clinician. The decision to wear one, and what to do with the data, has moved from a clinical conversation into the home, with the label rather than a clinician as the only written guidance.
A continuous glucose monitor reads the glucose concentration in interstitial fluid just under the skin, on a delay of several minutes, and uploads a 15-minute trace to a phone. For adults with type 1 diabetes, the data stream adjusts insulin doses. For athletes and biohackers, it tracks how food choices land. For a child whose pancreas is working normally, the trace will mostly sit flat in the middle of the normal range, with occasional excursions after a large bowl of pasta or a missed snack. Schofer's worry is that a flat trace with one spike, read by a parent trained to optimize, becomes data to act on even when the right answer is to ignore it.
A clinical-grade sensor will now reach two very different households. One is a clinical pediatric population: children with prediabetes, type 2 diabetes, severe obesity, or a strong family history of diabetes, for whom earlier detection of glycemic patterns could matter. About 1 in 3 U.S. adolescents has prediabetes or type 2 diabetes, and about 1 in 5 children has obesity, a baseline that frames the clinical case. For the other household, the worried-well parent of a healthy child, an audience the FDA never had to consider when CGMs were prescription-only but which Dexcom's parallel adult consumer marketing has been building for years, the same data tells parents almost nothing their next pediatric visit would not. Treating both groups as the same customer, with the same instruction leaflet, is the practical question the OTC clearance leaves open.
Robert F. Kennedy Jr.'s "Make America Healthy Again" campaign has been pushing CGMs as general-purpose self-tracking wearables for healthy adults, framing them as tools to take on chronic disease. The June clearance lands in that political tailwind. The FDA press release borrows the wellness market's vocabulary, language about glycemic awareness and long-term outcomes, in a population that no longer has a clinician gatekeeper.
A pediatric post-market surveillance study, tied to the 510(k) pathway and tracking outcomes in children under 12, is one piece the clearance does not name. Labeling that distinguishes the clinical child with diabetes risk from the worried-well child, with caregiver guidance for each, is another. Family-facing information that names disordered-eating risk and points parents to clinical help, written independently of Dexcom's marketing, is a third. A public FDA commitment to publish pediatric adverse-event data on a defined schedule is a fourth.
None of those appears in the June clearance notice. The first test will be what Dexcom files next: a pediatric post-market study commitment, a labeling refresh, or neither. If neither lands before a second generation of Stelo reaches the pharmacy, the gap between who the device was cleared for and who ends up wearing it will stay exactly where the clearance left it.